小胶质细胞
神经炎症
免疫系统
整合素αM
免疫组织化学
流式细胞术
生物
人口
抗原
髓样
分化群
单克隆抗体
免疫细胞化学
细胞
病理
免疫学
细胞生物学
化学
抗体
分子生物学
医学
炎症
生物化学
环境卫生
作者
Supinder S. Bedi,Philippa Smith,Robert A. Hetz,Hasen Xue,Charles S. Cox
标识
DOI:10.1016/j.jneumeth.2013.07.017
摘要
The inflammatory response after a CNS injury is regulated by microglia/macrophages. Changes in the ratio of M1 classically activated pro-inflammatory cells versus M2 alternatively activated anti-inflammatory cells reveal the direction of the immune response. These cells are routinely identified and enumerated by morphology and cell-surface markers using immunohistochemistry. We used a controlled cortical impact (CCI) mouse model for traumatic brain injury (TBI), then isolated microglia/macrophages from neural cell suspensions using magnetic beads conjugated to CD11b monoclonal antibody to obtain the entire myeloid population. Polarization states of CD11b+CD45lo microglia were evaluated by expression of M1 surface marker FcγRII/III and M2 surface marker CD206. After TBI, we observed an increase in M1:M2 ratio in the ipsilateral hemisphere when compared to the contralateral side, indicating that 24 h after CCI, a shift in microglia polarization occurs localized to the hemisphere of injury. Comparison with existing method(s): The major impetus for developing and refining the methods was the need to accurately quantify microglial activation states without reliance on manual morphometric counting of serial immunohistochemistry slides. Flow cytometric analysis of enriched cell suspensions provides quantitative measurement of microglial polarization states complementary to existing methods, but for entire populations of cells. In summary, we used immunomagnetic beads to isolate myeloid cells from injured brain, then stained surface antigens to flow cytometrically identify and categorize microglia as either classically activated M1 or alternatively activated M2, generating a ratio of M1:M2 cells which is useful in studying attempts to reduce or redirect neuroinflammation.
科研通智能强力驱动
Strongly Powered by AbleSci AI